Dr. Gruis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
90 Presidential Plz
4th Floor - Neurology
Syracuse, NY 13202Phone+1 315-464-4243Fax+1 315-464-5350
Education & Training
University of MichiganFellowship, Clinical Neurophysiology, 2002 - 2003- University of MichiganResidency, Neurology, 1999 - 2002
Johns Hopkins UniversityInternship, Internal Medicine, 1998 - 1999
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1998
Certifications & Licensure
MI State Medical License 2002 - 2027
NY State Medical License Active through 2013- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Trial of Early Noninvasive Ventilation for Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2007 Apr 01
- Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients Start of enrollment: 2008 Jan 01
Publications & Presentations
PubMed
- 35 citationsTrial of early noninvasive ventilation for ALS: A pilot placebo-controlled study.Teresa L. Jacobs, Devin L. Brown, Jonggyu Baek, Erin M. Migda, Timothy Funckes
Neurology. 2016-11-01 - 6 citationsHypoglossal nerve dysfunction and sleep-disordered breathing after strokeDevin L. Brown, Ronald D. Chervin, James Wolfe, Rebecca Hughes, Maryann Concannon
Neurology. 2014-04-01 - 34 citationsDiffusion tensor MRI of the corpus callosum in amyotrophic lateral sclerosisMolly C. Chapman, Laura Jelsone-Swain, Timothy D. Johnson, Kirsten L. Gruis, Robert C. Welsh
Journal of Magnetic Resonance Imaging. 2014-03-01
Press Mentions
U.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical StudyOctober 30th, 2024- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2022 Earnings Call TranscriptMarch 31st, 2023
- DiaMedica Therapeutics Announces Clinical Hold of Its Phase 2/3 ReMEDy2 Clinical Trial for DM199July 7th, 2022
- Join now to see all
Grant Support
- Pilot Placebo-Controlled Trial Of Early Noninvasive Ventilation For ALSNational Institute Of Neurological Disorders And Stroke2007–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
